Disc Medicine, Inc.
$71.41
▲
0.62%
2026-04-21 07:35:01
www.discmedicine.com
NGM: IRON
Explore Disc Medicine, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.74 B
Current Price
$71.41
52W High / Low
$99.5 / $39.2
Stock P/E
—
Book Value
$19.52
Dividend Yield
—
ROCE
-30.64%
ROE
-35.86%
Face Value
—
EPS
$-6.01
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
155
Beta
2.54
Debt / Equity
4.19
Current Ratio
21.94
Quick Ratio
21.94
Forward P/E
-8.82
Price / Sales
—
Enterprise Value
$1.77 B
EV / EBITDA
-7.54
EV / Revenue
—
Rating
Strong Buy
Target Price
$100.17
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | PharmaCyte Biotech, Inc. | $0.76 | — | $7.82 M | — | -8.38% | -8.24% | $1.51 / $0.63 | $3.59 |
| 2. | Allogene Therapeutics, Inc. | $2.42 | — | $582.63 M | — | -53.97% | -53.42% | $4.46 / $0.86 | $1.27 |
| 3. | Processa Pharmaceuticals, Inc. | $2.71 | — | $8.25 M | — | -250.81% | -3.73% | $19.63 / $1.76 | $2.17 |
| 4. | Eupraxia Pharmaceuticals Inc. | $7.2 | — | $599.04 M | — | -47.73% | -68.76% | $12.86 / $4.38 | $1.01 |
| 5. | MapLight Therapeutics, Inc. | $28.34 | — | $1.28 B | — | -36.5% | -56.19% | $31.13 / $12.24 | $10.41 |
| 6. | YD Bio Ltd | $5.31 | — | $382.42 M | — | -22.15% | -42.69% | $31 / $5.12 | $4.57 |
| 7. | IDEAYA Biosciences, Inc. | $33.6 | — | $2.95 B | — | -15.17% | -10.92% | $39.28 / $16.07 | $11.65 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -66.97 M | -67.7 M | -61.41 M | -39.95 M | -34.55 M | — |
| Net Profit | -60.53 M | -62.32 M | -55.25 M | -34.09 M | -29.46 M | — |
| EPS in Rs | -1.59 | -1.63 | -1.45 | -0.89 | -0.77 | -0.89 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -236.02 M | -129.72 M | -91.12 M | -47.48 M |
| Net Profit | -212.18 M | -109.36 M | -76.43 M | -46.83 M |
| EPS in Rs | -5.56 | -2.87 | -2 | -1.23 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 806.88 M | 496.77 M | 368 M | 200.21 M |
| Total Liabilities | 67.05 M | 53.19 M | 22.88 M | 23.61 M |
| Equity | 739.83 M | 443.59 M | 345.12 M | 176.6 M |
| Current Assets | 803.9 M | 493.62 M | 365.66 M | 198.49 M |
| Current Liabilities | 36.64 M | 23.32 M | 21.44 M | 22.58 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -180.39 M | -93.93 M | -73.46 M | -42.25 M |
| Investing CF | -394.3 M | -292.33 M | -0.09 M | -0.15 M |
| Financing CF | 473.41 M | 218.31 M | 239.38 M | 148.98 M |
| Free CF | -181.33 M | -94.43 M | -73.55 M | -42.4 M |
| Capex | -0.93 M | -0.51 M | -0.09 M | -0.15 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -43.08% | -63.22% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2022-12-30 | 1:0.0333333 |